Universitätsklinikum Carl Gustav Carus DIE DRESDNER. Welcome

Transkript

1 Universitätsklinikum Carl Gustav Carus DIE DRESDNER. Welcome Dear colleagues, This is already the third international symposium on therapeutic apheresis taking place in Dresden. The aim is to organize a high level international conference on Lipoprotein apheresis and Immunoadsorption for autoimmune diseases. We hope that the lectures by prominent invited speakers will spark lively discussions and complete a comprehensive overview on the potential of apheresis as well as ways to reach therapeutic targets. A special topic will be the presentation of new drugs for the treatment of hypercholesterolemia which have recently been developed or are already registered. 3rd Dresden International Symposium on Therapeutic Apheresis March 13 15, 2014 March 14, 2014 For this occasion, it is a pleasure to invite you to the beautiful city of Dresden, which, after decades of restauration shines anew these days. In fact, the University Hospital is just 15 minutes away from the very center of the old city. We hope to see you in Dresden. With best regards, Prof. Ulrich Julius Prof. Bernd Hohenstein Department of Medicine III University Hospital Dresden Germany

2 Lipoprotein apheresis Auditorium in the Dean s Building (House 40) Thursday, March 13, 2014 Friday, March 14, 2014 Saturday, March 15, 2014 Saturday, March 15, 2014 Chairpersons: Stefan R. Bornstein, Dresden; Markolf Hanefeld, Dresden CME-Punkte: 7 Chairpersons: Claudia Stefanutti, Rome; Gilbert Thompson, London CME-Punkte: 5 Chairpersons: Patrick Moriarty, Kansas City; Wolfgang Ramlow, Rostock CME-Punkte: 8 Chairpersons: Bernd Hohenstein, Dresden; H.E.L.P. Just more than LDL-Apheresis Lipoprotein(a) what s new? Borge Nordestgaard, Kopenhagen Screening activities for cardio-metabolic risk characterization Wolfgang Ramlow, Rostock Lipoprotein(a) as a risk factor in outpatients Sergey Tselmin, Dresden Effect of niacin on lipoprotein(a) level is dependent on apo(a) phenotypes Nadya Ertemeva, Moscow Efficacy of chronic lipoprotein apheresis in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease results of the prospective observational multicenter study Pro(a)LiFe Reinhard Klingel, Cologne Lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a) Tina Kahn, London Lipoprotein apheresis in patients with isolated elevated lipoprotein(a) effects on the incidence of cardiovascular diseases Elisabeth Steinhagen-Thiessen, Berlin Effect of lipoprotein apheresis on the coronary blood flow in patients with high lipoprotein(a) levels Klaus Peter Mellwig, Bad Oynhausen Influence of lipoprotein apheresis on the lipoprotein(a) levels in the long run Elisa Groß, Dresden Do we need a lipoprotein apheresis specific for lipoprotein(a) the Moscow experience Sergei Pokrovsky, Moscow; Marat Ezhov, Moscow Effects of lipoprotein apheresis on PCSK9 levels Influence of lipoprotein apheresis on the kinetics of lipoproteins Klaus Parhofer, Munic Lipoprotein apheresis and cholesterol efflux Tiziana Sampietro, Pisa Effect of acute cholesterol lowering on lipoproteins Patrick Moriarty, Kansas Effect of lipoprotein apheresis on cytokines new data Claudia Stefanutti, Rome New data on lipidomics in lipoprotien apheresis patients Jürgen Gräßler, Dresden Dynamics of complement and rheological indicators after the therapy with rheohemapheresis Milan Blaha, Hradec Kralove Rheological effects of lipoprotein apheresis Beate Jäger, Mülheim-Ruhr First data from the German-Lipoprotein-Apheresis Registry (GLAR) Volker Schettler, Göttingen Actual situation of lipoprotein apheresis in Saxony in 2013 Ulrike Emmrich, Dresden Detailed description of the cardiovascular situation in patients who have started an apheresis treatment Steffen Schampera, Dresden Long-term experience with lipoprotein apheresis Gennadi Konovalov, Moscow Gala Dinner (included) Swissôtel Dresden am Schloss, Schlossstraße 16, Dresden, Germany Results of a novel therapeutic vaccine for lipoprotein(a) in mice Hironori Nakagami, Osaka Lp(a) pathology at the molecular level and introduction of novel Lp(a) lowering therapies beyond apheresis Gerd Schmitz, Regensburg Therapeutic apheresis in prevention of restenosis after coronary angioplasty (first experience) Valeri Tishko, Sankt Petersburg Lipoprotein apheresis in patients with peripheral occlusive arterial disease Kathrin Enke-Melzer, Berlin Efficacy, safety and tolerability of long-term lipoprotein apheresis in patients with LDL- and Lp(a)-hyperlipoproteinemia: experience from 35,000 treatments in a single center Franz Heigl, Kempten Lipoprotein apheresis in children the Marburg experience Günter Klaus, Marburg Managing homozygous FH from cradle to grave Gilbert Thompson, London Pregnancy in homozygous familiar hypercholesterolemia when the things are going well Milan Blaha, Hradec Kralove Lomitapide in homozygous FH patients Maurizio Averna, Palermo Effect of lipids on cardiovascular autonomic regulation Tjalf Ziemssen, Dresden Nebenwirkungen der Lipoprotein-Apherese-Therapie Anja Ramlow, Rostock Pflegerische Aspekte der Apherese bei verschiedenen Behandlungsindikationen Ines Schulz-Merkel, Kempten Konsequenzen aus der steigenden Anzahl von Patienten in einem Apherese-Zentrum Kerstin Johne, Dresden HTG in an outpatient department significance as an atherosclerotic risk factor Moritz Scholz, Dresden Severe hyperchylomicronemia and hypertriglyceridemia: why, when and how it is to be treated Claudia Stefanutti, Roma Effect of lipoprotein apheresis on FABP4 long-term study Valeria Lamounier-Zepter, Dresden Comparison of two intravenous iron preparations in patients treated with lipoprotein apheresis Ulrike Schatz, Dresden Beyond extracorporeal lipoprotein apheresis impact on health-related quality of life in lipoproteinapheresis (LA) patients compared to patients with coronary heart disease (CHD) and to patients undergoing hemodialysis treatment (HD) Volker Schettler, Göttingen Psychische Situation von Apherese-Patienten im Vergleich zu Hämodialyse-Patienten Eva Stasiewsky, Dresden Concluding remarks PCSK9-inhibitors a new class of lipid-lowering drugs Ionna Gouni-Bertholdt, Cologne

3 Immunadsorption House 19 Room Friday, March 14, 2014 Auditorium in the Dean s Building (House 40) Friday, March 14, 2014 Friday, March 14, 2014 Chairpersons: Norbert Weiss, Dresden; Bernd Hohenstein, Dresden CME-Punkte: Immunoadsorption before and after renal transplantation Christian Hugo, Dresden Acquired Haemophilia: Conventional Treatment vs. Apheresis Heike Zeitler, Bonn Plasma exchange vs. immunoadsorption in steroid refractory neuroinflammatory demyelinating diseases Johannes Mühlhausen, Göttingen Immunoadsorption in autoimmune encephalitis Wolfgang Köhler, Wermsdorf Immunoadsorption in multiple sclerosis Bernd Hohenstein, Dresden Immunoadsorption in myasthenia gravis Kurt Derfler, Vienna Antibodies against AT1-receptor in transplantation (diagnostic, treatment, clinical relevance) Dagmar Barz, Jena Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease Johannes Mühlhausen, Göttingen Therapie der Präeklampsie mittels sflt-1-apherese Holger Stepan, Leipzig Immunoadsorption in thromboangitis obliterans Norbert Weiss, Dresden Immunoadsorption in Thromboangitis obliterans new data Peter Klein-Weigel, Berlin Chairpersons: Kurt Derfler, Vienna; Dagmar Barz, Jena Immunoadsorption in SLE Kurt Derfler, Vienna Immunoadsorption in children Theresa Kwon, Paris Immunadsorption in critical children in the hemato-oncology Volker Witt, Vienna Targeting supar in focal-segmental glomerulosclerosis by apheresis or immunoadsorption a therapeutic perspective? Christian Morath, Heidelberg Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic cardiomyopathy associated with diabetes mellitus Michael Dandel, Berlin Immunoadsorption after heart transplantation Nick Banner, Harefield New generation of affinity sorbents for therapeutic apheresis Sergei Pokrovsky, Moscow The effect of plasma exchange and immunoadsorption on the vaccination status Silke Rummler, Jena Diese Veranstaltung wird im Rahmen der strukturierten curriculären Fortbildung Lipidologie DGFF (Lipidologe DGFF ) als Fortbildungsnachweis anerkannt. Weitere Informationen hierzu sind erhältlich unter Rubrik Lipidologie DGFF. Vorsitzende: Sabine Fischer, Dresden; CME-Punkte: Jahre Lipid-Liga Ulrich Klör, Gießen Die aktuelle Rolle der HDL im Rahmen der Atherogenese Klaus Parhofer, München Neue Leitlinien zur Cholesterinsenkung: ACC/AHA, ESC/EAS und IAS: wer hat recht? Eberhard Windler, Hamburg Diagnostische und therapeutische Optionen bei Patienten mit hohen Lipoprotein(a)-Spiegeln Elisabeth Steinhagen-Thiessen, Berlin Omega-3-Fettsäuren in der Lipidtherapie Praktische Durchführung der medikamentösen lipidsenkenden Pharmakotherapie Sabine Fischer, Dresden Neue Entwicklungen in der lipidsenkenden Pharmakotherapie: Mipomersen, Lomitapide, PCSK9-Inhibitoren Heiner Bertholdt, Bielefeld Scientific Program supported by: Fresenius Medical Care GmbH Kaneka Pharma Europe N.V. B. Braun Avitum AG Miltenyi Biotec GmbH DIAMED Medizintechnik GmbH STADApharm GmbH Sanofi-Aventis Deutschland GmbH Breu GmbH medicap clinic GmbH AMGEN GmbH Aegerion Pharmaceuticals GmbH Novartis Pharma GmbH MSD Sharp & Dohme GmbH (1500 EUR) PakuMed GmbH Abbott Arzneimittel Deutschland (800 EUR) PENTRACOR GmbH Gemäß FSA-Kodex 20 Abs. 5 sind die im FSA vereinten Firmen verpflichtet, den Umfang des Sponsorings für Veranstaltungen offenzulegen. Jeweils für Werbemöglichkeiten und Standkosten. Die Offenlegung erfolgt auch im Internet und während der Veranstaltung.

4 Ke g le r - s t r. Z s chirn- s t ei n - s t r. H e y n a t h s t r. Bergm a n n s t r. 3rd Dresden International Symposium on Therapeutic Apheresis; March 13 15, 2014 How to find us Registration Registration form: Fetscherstraße 6/12 62 Pfotenhauerstraße Fiedlerstraße Blasewitzer Straße Overview University Hospital Dresden 19 6/12 Augsburger 40 Mildred-Scheel-Straße Mosenstr. A 17 str. Holbeinstr. e Tittmannstr. Haydnstr. straße Spenerstr. Geising-str. Stübelallee Bodenbacher Straße. Berset- Tetschener Beilstr. Brecht- Allee Karl- Roth- A 4 Herkulesstr. Geisingstr. Gorbitz Zwinglistr. Beilstr. Altstadt Weg Zwinglistr. Alemannenstr. Wartburgstr. Schubertstraße Pohlandplatz Altstriesen Eilenburger 6/12 Wittenberger Wormser Jacobistr. Tzschimmerstr. SchandauerStraße Comeniusstr. Clau ß st r. Hepkestr. Papstdorfer Rothermundtstr. Glashütter Prossener Mansf. Siebekingstr. Bodenbacher GRUNA Neustadt Schrammstein- Bräterstr. Vollsackstr. Schneebergstr. Berthold- Brandstr. Menzer- Sonnensteinweg Wiesenstr. Ostrauer Calvinstr. Bergmannstr. Wilder Mann Dreieck Dresden-Nord Eibenstocker Hauptbahnhof Junghansstr. Pohlandstr. Schlüter- straße str. A. Grüngürtel Bären A 13 Hellerau Am Ende Ulberndorfer Weg Am Lange Zeile Gartenheimallee Goethealle Königsheimplatz Merseburger Rosa- Augsburger Kipsdorfer Hepkestr. Baumzeile Anfang Graben- winkel Ruppendorfer Weg A 4 Flughafen Dresden-Süd H.-Clauß- Platz Hepkeplatz B.-Brecht- Platz Dreieck Dresden-West Falkensteinpl. Karcherallee Wolkensteiner Zrke i l- s t e in - s t r. irschher g Flughafen Kurzer Schritt Kleinhausweg Rosenbergstr. Rother - mundtpark Postelwitzer Hocksteinstr. Ermelstraße Junghansstr. Uttewalder Frauensteiner Platz Gerader Steg Dornblüthstr. Händelallee Gottleubaer Postgang Lauensteiner Eibenstocker Am Knie Behrisch- Witten- Schandauer Stadtplanausschnitt Bhf. Neustadt Thiemestr. Striesener Friedhof Bärensteiner Glasewaldtstr. Dornblüthstr. Kipsdorfer Zinnwalder Fürstenwalder Voglerstr. aße Glasewa A Glashütter University Hospital Dresden Department of Medicine III International Travel Dresden International airport is approximately 30 minutes from the clinical center and served by regional railway. International trains arrive both at Dresden main station and at Dresden Neustadt with convenient connections to tramway lines. Public Transport The University Hospital is served by tramway lines 6 and 12 (Stop: Augsburger Straße/ Universitätsklinikum) as well as bus lines 64 and 62 (Stop: Universitätsklinikum). Car For fee parking is available at the Fiedlerstraße main entrance parking deck with room for 500 cars. Please register by sending or faxing the attached form to the Carl Gustav Carus Management GmbH. You can also register via CGCManagementGmbH@uniklinikum-dresden.de Or write an to: ulrich.julius@uniklinikum-dresden.de The registration fee for participants is 80 EUR by March 01, 2014 thereafter the registration fee will be 100 EUR (physicians / scientists in training 40 EUR, students (with ID) 20 EUR). The Gala Dinner will be included. CME points have been affirmed by the Sächsische Landesärztekammer. Updated information about the symposium including the scientific program will be provided on the following website: Bank: Deutsche Kreditbank AG Account No.: Bank code: IBAN: DE BIC: BYLADEM 1001 Please send or fax this filled form to the conference agency until February 28, 2014! Carl Gustav Carus Management GmbH Phone: Fetscherstr. 74 Fax: CGCManagementGmbH@ uniklinikum-dresden.de 3rd Dresden International Symposium on Therapeutic Apheresis (Teilnahme kostenfrei / DGFF Lipid-Liga e.v.) Surname Title Address First Name Registration fee (Financial Management: CGC Management GmbH) 80 (before March 01, 2014) Physician/Scientist in Training 20 Student (with ID) Participation in Gala Dinner March 14, 2014 Yes No I will pay by bank transfer. Bank: Deutsche Kreditbank AG Für die vertragliche und finanzielle Abwicklung dieser Veranstaltung zeichnet die Carl Gustav Carus Management GmbH verantwortlich. IBAN: DE BIC: BYLADEM 1001 I will pay by credit card. I authorize the charge of the registration fee. VISA MASTERCARD Card No.: Expiry date: / Cardholder: Date: Signature:

5 Antwort Carl Gustav Carus Management GmbH Germany